HTA Monthly Wrap - August 2021
August 31, 2021

HTA Monthly Wrap - August 2021

Your Journey

During this period of COVID-19 lockdowns and increased alert levels, we hope this edition of the HealthTech Activator (HTA) Monthly Wrap finds you well. 

This month we bring updates on planned events, an e-Learning course available for signup, an overview of valuation from Jai Basrur of CGB Consulting, and more - check out the links below for further details.


HTA News & Events

HTA Capital Planning Workshop

29 September 2021

Presented by Tim McCready of BioPacific Partners, this programme is tailored for the specific challenges of capital raising faced by healthtech companies.

We encourage those early to mid stage healthtech companies seeking to raise capital for the first time outside their immediate contacts to attend.

Register for this session here.

Quality Management System eLearning (Online)


The Quality Management System (QMS) Primer is a wholly online, self-paced course providing an overview of quality management systems, their benefits and what you need to consider before implementation.

It is provided by Seerpharma and is supported and fully funded by the REDI initiative, powered by MTPConnect, so there is no cost to you for this programme. 

Read more and register here.

HTA In-Depth Market Validation Programme

Expressions of interest open for February 2022

As mentioned in our July Monthly Wrap, expressions of interest for healthtech companies to join the Feb 2022 In-Depth Market Validation cohort are now open. Contact the HTA Coordinator, Jamie Attenborough (email linked here), if you’re interested in the programme or would like further information.


Valuation Overview - An Art and a Science

Jai Basrur, CGB Consulting

To understand how to value a healthtech company it is first important to understand the nuances of valuation. In this article, Jai Basrur provides a comprehensive overview of valuation, from definition through to typically used valuation methods and considerations. 

Read more here.


Community Insights 

Insides Company Raise: 

Bowel device startup raises $4m in Series A round (NBR)

  • With anticipated FDA approval in early 2022 and first sales in Europe, The Insides Company is hoping for a $6m raise by second close.

Commercialising Cancer Tests: 

TIN Member Spotlight: Pacific Edge

  • After reporting accelerating revenues in FY21, Pacific Edge is in the TIN spotlight talking regulatory strategy, Covid-19 challenges, and more.

CRISPR Breakthrough: 

CRISPR Hits Home in a First-in-Human Study (abstract only)

  • NZ investigators Ed Gane and Justin Kao, and two NZ patients, were involved in a recently published in-vivo gene editing trial for Transthyretin Amyloidosis with promising results.
Download PDF
Read on External Site